JW홀딩스

096760KOSPI기타 금융업

55.5 / 100

Reference Date: 2026-06-10

Financial Score25.0 / 40

News Sentiment12.5 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Declined 8.9% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

JW Holdings is a holding company established in 2007 through a spin-off from JW Chungwa Pharmaceutical, overseeing overseas operations and management services for its subsidiaries. In 2025, its revenue decreased by 6.3% to 933 billion won, with key products including nutrient solutions, penem antibiotics, and itraconazole. Major subsidiaries include JW Chungwa Pharmaceutical, JW Shin Yak, and JW Life Science, producing pharmaceuticals, medical devices, and infusion solutions.

Number of Employees

128people

Average Salary

68.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

2.40Industry Average 9.688.0Point

Half of industry avg (excellent)

PBR

0.47Industry Average 0.462.5Point

Higher than industry avg (caution)

ROE

20.70Industry Average 5.417.0Point

3.8x industry avg (excellent)

Debt Ratio

30.24Industry Average 16.690.5Point

1.8x industry avg (risky)

Trend 2023~20257.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲2.4% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲7.9% (2-year basis)

ROE Trend

4.0 / 4

Avg ROE 19.3% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position5.0Point

52w mid range (45%)

Current 3,755Won52-week high 4,47052-week low 3,165

1-month return1.0Point

1m -8.86% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral기업지배구조보고서공시2026-06-01
Neutral분기보고서 (2026.03)2026-05-15
Neutral영업(잠정)실적(공정공시)2026-05-12